AGP Executive Report
Last update: 6 hours agoBoston Marathon: Registration opens for the 131st Boston Marathon, adding a new lottery for qualifying runners who miss the cutoff—aimed at keeping hopes alive as standards tighten. Cancer & biotech (Massachusetts): Telix won FDA approval for a new brain cancer imaging agent (FET-PET), a potential boost for glioma diagnosis and treatment planning at Mass General Brigham. Obesity drug pipeline (Massachusetts): Alveus launched its Phase 2 PRESERVE trial for ALV-100 to help people sustain weight loss after semaglutide; Corbus posted positive topline Phase 1b data for oral CRB-913, with a 5% mean weight loss at 12 weeks. Kidney disease trials (Massachusetts): Akebia dosed the first patient in a Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseases, with early data expected in 2027. Public health policy: Maryland and Illinois issued new vaccine schedules/guidance, making recommendations and coverage rules vary by state. Care access & workforce: Boston Medical Center nurses voted to authorize a three-day strike over pay and staffing.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
